Metraipolis › archive › dc_f3ea565b5d94

Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer… — Europe PMC PMID:42828095

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42828095
DOI
10.1016/j.esmorw.2026.100783
License (as archived)
solo-consultazione
Archived
2026-10-06T07:52:17.646Z
SHA-256 of the archived text
641df4d04aead490d6aa4e48badeb7fe33149f14c29b1e915c71c8fa9b359c1b
Stable URL of this page
https://metraipolis.com/documento/dc_f3ea565b5d94

How to cite

Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer… — Europe PMC PMID:42828095 — Europe PMC (en), https://europepmc.org/article/MED/42828095 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f3ea565b5d94 (Metraipolis archive dc_f3ea565b5d94, sha256 641df4d04aead490d6aa4e48badeb7fe33149f14c29b1e915c71c8fa9b359c1b)
BibTeX
@misc{dcf3ea565b5d94,
  title = {Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer… — Europe PMC PMID:42828095},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42828095},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f3ea565b5d94; sha256 641df4d04aead490d6aa4e48badeb7fe33149f14c29b1e915c71c8fa9b359c1b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42828095. Agents can read the archived copy with the MCP tool read_document.